van Dam Laura S, de Zwart Verena M, Meyer-Wentrup Friederike A G
Department of Pediatric Hematology and Oncology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands.
Pediatr Blood Cancer. 2015 Feb;62(2):190-197. doi: 10.1002/pbc.25284. Epub 2014 Oct 18.
Programmed cell death-1 (PD-1) and its ligands, PD-L1 and PD-L2 maintain self-tolerance and modulate physiological immune responses. Recently, targeting the PD-1/PD-L1 pathway with blocking antibodies has emerged as a potentially promising approach to treat advanced cancers in adult patients. Since tumor PD-L1 expression is currently considered the most important predictive biomarker for successful checkpoint blockade, we summarize expression data for the most common tumors of childhood. Additionally, we give an introduction into PD-1 function in the immune system to then focus on PD-1 mediated tumor immune escape. Pediatr Blood Cancer 2015;62:190-197. © 2014 Wiley Periodicals, Inc.
程序性细胞死亡蛋白1（PD-1）及其配体PD-L1和PD-L2维持自身耐受性并调节生理性免疫反应。近来，使用阻断抗体靶向PD-1/PD-L1通路已成为治疗成年患者晚期癌症的一种潜在的有前景的方法。由于肿瘤PD-L1表达目前被认为是成功进行检查点阻断的最重要预测生物标志物，我们总结了儿童期最常见肿瘤的表达数据。此外，我们介绍了PD-1在免疫系统中的功能，随后重点阐述PD-1介导的肿瘤免疫逃逸。《儿科血液与肿瘤学》2015年；62:190 - 197。©2014威利期刊公司
